Supernus RENAISSANCE 2 Please see below for Epilepsy Research Opportunity. For more information please contact: Jacara WashingtonClinical Research CoordinatorP: 716-961-9220E: jawashington@dentinstitute.com
Supernus RENAISSANCE 2 Read More »
Migraine prevention injection in patients with unsuccessful prior preventive treatments The objective of the trial is to assess the efficacy of the study drug for prevention of migraine at different doses compared to placebo in patients who have failed multiple preventive treatments. Inclusion Criteria: In order to be eligible, you have to have at least
Migraine prevention injection in patients with unsuccessful prior preventive treatments Read More »
Chronic Migraine Implant for Migraine Prevention (RELIEV-CM2) The purpose of the RELIEV-CM2 study is to evaluate ShiraTronics Migraine Therapy System’s ability to reduce the frequency of headaches for those living with chronic migraine. Inclusion Criteria: You may be eligible for this study if your doctor has diagnosed you with chronic migraine and you meet the
Chronic Migraine Implant for Migraine Prevention (RELIEV-CM2) Read More »
Menstrual Migraine Prevention using Ubrelvy This study will evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension Inclusion Criteria: In order to be eligible for this study, you must be at least 18 years old and have a diagnosis of Menstrual Migraine What to Expect
Menstrual Migraine Prevention Read More »
Generation HD-2 This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with a placebo in participants with prodromal and early manifest Huntington’s Disease. Inclusion Criteria: Visit link below for more info: Ages Eligible for Study: 25 Years to 50 Years (Adult) Sexes Eligible for Study: All Generation HD-2 Link
ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI) and dementia (DEM). Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 750 participants will be newly
